Clinical trial NCT05118113: Development of a Cell Culture Process for the Production of Human T-lymphocyte Precursors
Official title: Development of a Cell Culture Process for the Production of Human T-lymphocyte Precursors
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Healthy Volunteers
Lead sponsor: Smart Immune SAS
Sponsor class: INDUSTRY
First posted: 2021-11-11
Enrollment: 14
Sex: MALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The purpose of this study is to finalise the development of a process for the production of T-cell progenitor cells.


Eligibility criteria: Inclusion Criteria:

* Healthy donors, men aged 18 to 40 years.
* Body weight ≥ 65 kg with a body mass index (BMI) calculated by weight in kg/(height in m)² of 20 to 30 kg/m² at screening.
* Informed consent form signed and dated prior to any study-specific screening procedure.
* Health status judged by the investigator to be compatible with participation in the study based on medical history, results of physical examination, results of biological laboratory tests (cell blood count including RBC, hematocrit, hemoglobin, reticulocytes, WBC, platelet, PT, aPTT, CRP, fasting blood glucose, ionogram (Na+, K+, Cl-, HCO3-), creatinine, creatinine clearance by Cockcroft, albumin, total protein, total bilirubin, AST, ALT, ALP, GGT), vital signs measurements and 12-lead ECG. All results should be normal or, if out of range, clinically insignificant in the judgement of the investigator.
* Venous capital compatible with leukapheresis
* Have a high probability of complying with and completing the study.
* Be affiliated with a Social Security scheme

Exclusion Criteria:

* Any cardiovascular (e.g. heart failure), hepatic, renal, respiratory (e.g. asthma), gastrointestinal, endocrine (e.g. diabetes, dyslipidemia), immunological, dermatological, haematological (including hemoglobinopathy), neurological, psychiatric disorder or any history of allergy to a drug.
* State of acute illness (e.g., vomiting, fever, diarrhea) within 7 days prior to the first day of the study.
* History of drug abuse in the year preceding the first day of the study.
* History of alcoholism in the year prior to day 1 defined as consumption of more than 3 standard drinks/day (30 g/day) or 15 standard drinks/week (150 g/week) or less than two non-alcoholic days each week, or more than 5 standard drinks (50 g) on a single occasion.
* Any contra-indication to filgrastim
* Positive serological results for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, syphilis and/or human T-lymphotropic virus (HTLV).
* Positive urine drug tests (methadone, barbiturates, benzodiazepines, tricyclic antidepressants, cocaine, cannabinoids, morphine, amphetamines and methamphetamines, including 3,4-methylenedioxy-N-methylamphetamine \[MDMA\]).
* Laboratory workup including blood count, fasting blood glucose, blood ionogram, creatinine, AST, ALT, gamma GT, alkaline phosphatase, total bilirubin, CRP, PT, aPTT incompatible with leukapheresis protocol.
* Use of any experimental drug within 30 days prior to inclusion.
* Use of any prescription or over-the-counter medication within 5 times the elimination half-life prior to inclusion. However, any prescribed medication that may interfere with the study objectives must be discontinued for at least 30 days.

Primary outcomes:
measure: Production of cell therapy products fulfilling the required specifications
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: CIC Paris Est, Hôpital Pitié Salpêtrière
Study officials:
affiliation: CIC Paris Est, Hôpital Pitié Salpêtrière, Paris
name: Joe-Elie Salem, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: